Prelude to prioritize development of mutant selective JAK2V617F JH2 inhibitor and KAT6A selective degrader programsPausing further clinical ...
Update on WTX-124 Phase 1/1b clinical trial interim data and End of Phase 1 meeting with the U.S. Food & Drug Administration ...
TELUS Digital’s Fuel iX™ brings AI to every team member, enabling secure, scalable innovation and better customer experiences ...
Silicon Labs , the leading innovator in low-power wireless, reported financial results for the third quarter, which ended October 4, ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback